Fundraising Fox
Sanegene Bio
Boston, US · Founded 2021 · 33 employees on LinkedIn · 2 known investors
Find your way into Sanegene Bio
Sign up to see every warm intro you have to Sanegene Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Sanegene Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
SanegeneBio is a biotech company developing RNA interference (RNAi) genetic medicines for obesity, cardiometabolic, and autoimmune diseases. Its LEAD (Ligand and Enhancer Assisted Delivery) platform enables tissue-specific gene silencing in the liver, adipose tissue, muscle, and immune cells via subcutaneous dosing.
Founders & leadership
Sanegene Bio was founded in 2021 by Shiyu Wang.
SW
Shiyu WangCo-founder and CSOShiyu Wang is a research scientist with over six years of experience in liver biology and preclinical drug discovery. With training in biochemistry, he has expertise in in vitro and in vivo pharmacology, assay development, and antisense oligonucleotide therapeutics.
WW
Weimin WangFounder
WW
Weimin Wang, Ph.D.Founder, Chief Executive Officer
SW
Shiyu Wang, Ph.D.Co-Founder, Chief Scientific Officer
Investors · 2
Qiming Venture Partnerslisted by Qiming Venture PartnersBeijing
How we know: Qiming Venture Partners's portfolio page · the VCSheet dataset · Not right? Tell us
Related companies · 3
Day One BiopharmaceuticalsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Sana BiotechnologySana is a biotech company developing engineered cell medicines, including gene therapies for gene modification and delivery, cell replacement therapies using stem cell biology, and manufacturing solutions to improve patient access to these treatments.
Companies working in the same space as Sanegene Bio.
Frequently asked questions
- What does Sanegene Bio do?
- SanegeneBio is a biotech company developing RNA interference (RNAi) genetic medicines for obesity, cardiometabolic, and autoimmune diseases. Its LEAD (Ligand and Enhancer Assisted Delivery) platform enables tissue-specific gene silencing in the liver, adipose tissue, muscle, and immune cells via subcutaneous dosing.
- Who founded Sanegene Bio?
- Sanegene Bio was founded by Shiyu Wang in 2021.
- Who are Sanegene Bio's investors?
- Sanegene Bio's investors include Qiming Venture Partners, Vivo Capital.
- Where is Sanegene Bio headquartered?
- Sanegene Bio is headquartered in Boston, US.